Newsroom | 220420 results

Sorted by: Latest
Health
-

Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present new preclinical data across two posters at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The presentations expand the growing body of evidence supporting the company’s vector engineering platform, which is designed to achieve cell-type-selectiv...
-

Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines...
-

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting supporting the intracerebroventricular (ICV) route of administration as a routine approach for delivering medicines, including gene therapies, to treat central nervous system (CNS) disorders. The presentation furt...
-

Tolion Health AI Announces Launch of Tolion Brain Coach, First AI-Driven Personalized Mobile Application for Brain Health, Longevity, and Prevention of Alzheimer's Disease and Dementia

BOSTON--(BUSINESS WIRE)--Tolion Health AI, a digital health company developing personalized, preventive, and predictive AI solutions for brain health, today unveiled the latest tool in its Brain Health Platform, the Tolion Brain Coach mobile application. Built to combine advanced medical research with user-specific behaviors and data, the new app delivers precise, actionable and personalized insights to improve brain health. "Prevention is essential to reducing the public health and economic im...
-

Mirai Bio Presents Data Showing Rapid Advancement of Novel CD8+ T-Cell Targeted LNPs to Functional NHP Proof-of-Concept at ASGCT 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mirai Bio Presents Data Showing Rapid Advancement of Novel CD8+ T-Cell Targeted LNPs to Functional NHP Proof-of-Concept at ASGCT 2026...
-

Infinitopes Appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to Advance Therapeutic Pipeline From Clinical to Commercialisation

OXFORD, England & BOSTON--(BUSINESS WIRE)--Infinitopes, a biotechnology company developing novel and precision immunotherapy, today announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer. Dr. Brewer, a pioneer and recognised industry leader in cancer immunotherapy and cell therapies, has served as a non-executive director (NED) of the company since March 2025, now joining the executive leadership team at a key inflection point in the company...
-

訂正・差し替え サムスンエピスホールディングス、2026年度第1四半期決算を発表

韓国・仁川--(BUSINESS WIRE)--（ビジネスワイヤ） -- バイオ医薬品およびバイオテクノロジー分野のイノベーションに特化した投資会社であるサムスンエピスホールディングス（KRX：0126Z0）は、2026年度第1四半期の業績を発表しました。 サムスンエピスホールディングスの社長兼最高経営責任者（CEO）であるキム・キョンアは、次のように述べています。「当四半期のサムスンバイオエピスは、バイオシミラー・ポートフォリオ全体で勢いが継続したことを背景に、堅調な成長を達成しました。当社は新たなグローバル・パートナーシップの構築とポートフォリオ拡充を通じて、さらに地位を強化しています。欧州で初のバイオシミラー発売から10周年を迎えるにあたり、 これまで築いてきた実績を基盤としながら、長期的成長を支える戦略的投資に引き続き注力していきます。当社は今後も株主の皆さまに持続的な価値を提供することに尽力します。」 2026年度第1四半期業績 サムスンバイオエピスは、2026年度第1四半期の単体ベースで、売上高4,549億ウォン、営業利益1,440億ウォンを計上しました。第1四半期の売上...
-

Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets

MEDOLLA, Italy--(BUSINESS WIRE)--“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. Sahara has lived with a serious heart condition since early adolesce...
-

Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001

BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company’s lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome. The trial aimed to investigate the efficacy, safety, tolerability and pharmacokinetics of inhaled ETD001 in the 10%...
-

再生医療における画期的なBEES-HAUS細胞療法（パラクリン効果と細胞の定着による尿道狭窄症治療）を簡略化したBHES-HAUSの臨床結果をAUA 2026で発表

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- BEES-HAUS細胞療法による尿道狭窄の創傷治癒メカニズムを解明した画期的な科学的発見が、インド、日本両国の医師・科学者チームにより報告されました。臨床的な安全性と有効性を示すものであり、再生医療におけるこのような発見は初めてとなります。 この研究では、尿道狭窄の治療に２次元（2D）培養された自己口腔粘膜上皮細胞群と、フェスティゲル(Festigel)スキャフォールドで３次元（3D）培養された同細胞群 を混合するハイブリッドアプローチが採用されました。2次元培養細胞が産生するIGF-1のパラクリン効果と、３次元培養細胞の切開創への生着が相まって尿道上皮欠損を修復するというメカニズムが考察され、結果がFrontiers in Urology誌に発表されました。研究者らは、この成果は、in vitroの組織工学で培養された細胞が、in vivoでの治療で良好な臨床結果を出したという意味で世界初のものであり、尿道上皮の損傷の回復につながっていると指摘しています。また、患者にとっては狭窄の再発の可能性が少なく、生活の質を向...